1Sandler A B,Gray R,Brahmer J,et al.Randomized phase Ⅱ/Ⅲ trial of paclitaxel(P)plus carboplatin (C) with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer(NSCLC):An Eastern Cooperative Oncology Group (ECOG) trialE4599.Pro Am Soc Clin Oncol,2005,23:2s LBA4.
2Half E,Broaddus R,Danenberg K D,et al.HER-2 receptor expression,localization,and activation in colorectal Cancer cell lines and human tumors.Int J Cancer,2004.108:540-548.
3Sekharam M,Zhao H,Sun M,et al.Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x (L) pathway.Cancer Res,2003,63:7708-7716.
4Chun Y J,Park S,Yang S A,et al.Activation of Fas receptor modulates cytochrome P450 3A4 expression in human colon carcinoma cells.Toxicol Lett.2003.146:75-81.
8Li E, Clark A M, Hufford C D.Antifungal evaluation of pseudolaric acid B, a major constituent of Pseudolarix kaempferi. J Nat Prod, 1995, 58:57
9Tan W F, Zhang X W, Li M H, et al. Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect. Eur J Pharmacol, 2004, 499:219
10Pan D J, Li Z L, Hu C Q,et al.The cytotoxic principles of Pseudolarix kaempferi: pseudolaric acid-A and-B and related derivatives. Planta Med, 1990, 56:383-385
